Background The combination of the inhaled muscarinic antagonist umeclidinium (UMEC)
with the long-acting β2-agonist vilanterol (VI) has been shown to provide significant …

Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …

BACKGROUND: Umeclidinium (UMEC; GSK573719) is a new long-acting muscarinic
antagonist (LAMA) currently in development in combination with vilanterol (VI), an inhaled …

Background Combination of the inhaled long-acting muscarinic antagonist umeclidinium
(UMEC; GSK573719) with the long-acting β2-agonist vilanterol (VI) is an approved …

Background The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the
combination of UMEC with the long-acting β 2-agonist (LABA) vilanterol (UMEC/VI) are …

Background Combination long-acting bronchodilator therapy may be more effective than
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the …

Background: The long-acting muscarinic antagonist umeclidinium (UMEC) is in
development as monotherapy and in combination with the long-acting beta-2 agonist …

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality
and health care expenditure throughout the world. COPD guidelines recommend the use of …

Background The role of umeclidinium plus vilanterol as a combination therapy for chronic
obstructive pulmonary disease (COPD) has not yet been clearly defined. Objective The aim …

Background The combination of umeclidinium (UMEC), a long-acting muscarinic receptor
antagonist, and vilanterol (VI), a selective long-acting β2 agonist, is in development for the …